<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="editorial" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1079783</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2022.1079783</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Treatment of Alzheimer&#x2019;s disease-discovery of natural products based on neurite outgrowth and neuroprotection</article-title>
<alt-title alt-title-type="left-running-head">Yang et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2022.1079783">10.3389/fphar.2022.1079783</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yang</surname>
<given-names>Zhiyou</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/431330/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Song</surname>
<given-names>Cai</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/254299/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ge</surname>
<given-names>Yue-Wei</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1567961/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tohda</surname>
<given-names>Chihiro</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/274642/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Guangdong Provincial Key Laboratory of Aquatic Product Processing and Safety</institution>, <institution>College of Food Science and Technology</institution>, <institution>Institute of Nutrition and Marine Drugs</institution>, <institution>Guangdong Ocean University</institution>, <addr-line>Zhanjiang</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM</institution>, <institution>Guangdong Pharmaceutical University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Section of Neuromedical Science</institution>, <institution>Institute of Natural Medicine</institution>, <institution>University of Toyama</institution>, <addr-line>Toyama</addr-line>, <country>Japan</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited and reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3481/overview">Nicholas M. Barnes</ext-link>, University of Birmingham, United Kingdom</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Zhiyou Yang, <email>yang_zhiyou@sina.com</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>11</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>1079783</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>10</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>10</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Yang, Song, Ge and Tohda.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Yang, Song, Ge and Tohda</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" journal-id="Front. Pharmacol." xlink:href="https://www.frontiersin.org/researchtopic/31034" ext-link-type="uri">Editorial on the Research Topic <article-title>Treatment of Alzheimer&#x2019;s disease-discovery of natural products based on neurite outgrowth and neuroprotection</article-title>
</related-article>
<kwd-group>
<kwd>Alzheimer&#x2019;s disease</kwd>
<kwd>natural products</kwd>
<kwd>neurite outgrowth</kwd>
<kwd>neuroprotection</kwd>
<kwd>anti-neuroinflammation</kwd>
<kwd>brain microenvironment</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Alzheimer&#x2019;s disease (AD) is an aging-related progressing neurodegenerative brain disorder. Extracellular neuritic plaques composed of misfolded amyloid &#x3b2; (A&#x3b2;) proteins and intracellular neurofibrillary tangles formed by hyperphosphorylated tau protein are the two typical characteristics of AD. Although AD has been reported for over 100 years, the intrinsic mechanism remains elusive and there are still no well-established clinical strategies to cure or even prevent this disease. Most of the designed molecules targeting A&#x3b2; and tau fail to improve cognitive function in clinical trials. Neurite atrophy and synaptic loss underlie the upstream of neuronal death and directly lead to memory impairment in AD (<xref ref-type="bibr" rid="B1">Dickson and Vickers, 2001</xref>). Thus, targeting neurite regeneration and synaptic reformation to reconstruct neuronal networks may provide promising therapeutic strategies for AD (<xref ref-type="bibr" rid="B6">Tohda, 2016</xref>). This research topic aimed to focus on natural products as novel therapeutics for AD based on neurite regeneration and neuroprotection.</p>
<p>The accumulation of A&#x3b2; oligomers promotes axonal transport impairment and follows mitochondrial dysfunction in the distal of neurites, leading to axonal degeneration (<xref ref-type="bibr" rid="B5">Salvadores et al., 2020</xref>). In addition, <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.921611/full">Ooi et al.</ext-link> demonstrated that glyceraldehyde-derived advanced glycation end-products (AGEs), involved in diabetes mellitus-associated AD, triggered tau hyperphosphorylation and abnormal aggregation of toxic AGE-&#x3b2;-tubulin complexes, thus inhibiting neurite outgrowth in human neuroblastoma SH-SY5Y cells. Meanwhile, the AGE inhibitor aminoguanidine and pyridoxamine inhibited the formation of AGE-&#x3b2;-tubulin complexes and mitigated the glyceraldehyde-induced suppression of neurite outgrowth.</p>
<p>Natural products are promising resources for AD intervention, a systematic strategy has been proposed to discover bioactive candidates in natural medicines based on neurite outgrowth, and subsequently to identify target proteins of bioactive compounds by means of drug affinity responsive target stability (DARTS) analysis (<xref ref-type="bibr" rid="B7">Yang et al., 2017</xref>). Furthermore, the saponins from <italic>Eleutherococcus senticosus</italic> showed neurite elongation effects in primary cultured cortical neurons and correlated with memory enhancement in normal rats, and 26 saponins were clarified penetrating the blood&#x2013;brain barrier (<xref ref-type="bibr" rid="B3">Huang et al., 2022</xref>). <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2021.794458/full">Shi et al.</ext-link> investigated the memory ameliorative effects of baicalein, a well-known flavone, in A&#x3b2;42 hippocampal CA1 injected model mice. As a result, baicalein remarkably attenuated A&#x3b2;-induced neurite atrophy, spine loss, synaptic dysfunction, and cognitive deficits.</p>
<p>Glial cells play important roles in maintaining brain microenvironmental homeostasis. In response to A&#x3b2; stimuli, microglia NLRP3 assembles adaptor protein ASC and procaspase-1 into an inflammasome complex to induce the caspase-1 mediated secretion of IL-1&#x3b2;/IL-18, accompanied by a microglial switch from the protective M2 phenotype to the inflammatory M1 phenotype (<xref ref-type="bibr" rid="B2">Heneka et al., 2013</xref>). M1 microglia exerts low expression of degradation enzymes and decreased ability to engulf and degrade A&#x3b2;, resulting in increased A&#x3b2; deposits. While, naringenin, a natural flavanone, is able to transform the phenotype of M1 microglia to M2 microglia, and increase the expression of A&#x3b2; degradation enzymes including neprilysin and insulin degradation enzyme (<xref ref-type="bibr" rid="B8">Yang et al., 2019</xref>). The secreted IL-1&#x3b2; from M1 microglia triggers neuronal tau hyperphosphorylation <italic>via</italic> enhancing CaMKII-&#x3b1; and inhibiting PP2A activity (<xref ref-type="bibr" rid="B4">Ising et al., 2019</xref>). However, M2 microglia secreted IL-4 inhibits the phosphorylation of tau, thereafter, creating a beneficial microenvironment for the maintenance of regenerated axons. <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.849994/full">Tang et al.</ext-link> reported that a Chinese medicine formula 9002A ameliorated the increased expression of APP and memory deficits in an A&#x3b2;<sub>1-42</sub> brain-injected mouse model. <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2021.607403/full">Sohn et al.</ext-link> investigated a food and medicinal plant, <italic>Ficus erecta</italic>, which could inhibit the activation of microglia and IL-1&#x3b2; production in icv A&#x3b2;<sub>1-42</sub> injected mice. Furthermore, A&#x3b2;<sub>1-42</sub>-induced A&#x3b2; deposits, neuronal death, and cognitive impairment were also alleviated by <italic>Ficus erecta</italic> ethanol extracts treatment. In addition, <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.960112/full">Han et al.</ext-link> summarized the lignans, especially dibenzocyclooctene lignans, as potential anti-AD candidates for extensive pharmacological effects such as anti-neuroinflammation, neurite regeneration, and neuro-protection.</p>
<p>Collectively, neurite regeneration is essential for memory reconstruction, while modulating a beneficial microenvironment by removing toxic AGEs, A&#x3b2; plaques, phosphorylated tau protein, and inflammatory cytokines is required for the maintenance of regenerated neurites (<xref ref-type="fig" rid="F1">Figure 1</xref>). Thus, muti-targeting therapies hold great potential to treat AD and traditional medicine-derived natural products precisely correspond to this characteristic.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Neurite regenerative strategy as potential AD therapy.</p>
</caption>
<graphic xlink:href="fphar-13-1079783-g001.tif"/>
</fig>
</body>
<back>
<sec id="s1">
<title>Author contributions</title>
<p>ZY wrote the first draft of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.</p>
</sec>
<sec id="s2">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s3">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickson</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Vickers</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>The morphological phenotype of &#x3b2;-amyloid plaques and associated neuritic changes in Alzheimer&#x2019;s disease</article-title>. <source>Neuroscience</source> <volume>105</volume>, <fpage>99</fpage>&#x2013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/s0306-4522(01)00169-5</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heneka</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Kummer</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Stutz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Delekate</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vieira-Saecker</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>NLRP3 is activated in Alzheimer&#x27;s disease and contributes to pathology in APP/PS1 mice</article-title>. <source>Nature</source> <volume>493</volume>, <fpage>674</fpage>&#x2013;<lpage>678</lpage>. <pub-id pub-id-type="doi">10.1038/nature11729</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X. T.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Memory enhancement effect of saponins from <italic>Eleutherococcus senticosus</italic> leaves and blood-brain barrier-permeated saponins profiling using a pseudotargeted monitoring strategy</article-title>. <source>Food Funct.</source> <volume>13</volume>, <fpage>3603</fpage>&#x2013;<lpage>3620</lpage>. <pub-id pub-id-type="doi">10.1039/d1fo03078g</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ising</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Venegas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Scheiblich</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>S. V.</given-names>
</name>
<name>
<surname>Vieira-Saecker</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>NLRP3 inflammasome activation drives tau pathology</article-title>. <source>Nature</source> <volume>575</volume>, <fpage>669</fpage>&#x2013;<lpage>673</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1769-z</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salvadores</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ger&#xf3;nimo-Olvera</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Court</surname>
<given-names>F. A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Axonal degeneration in AD: The contribution of A&#x3b2; and tau</article-title>. <source>Front. Aging Neurosci.</source> <volume>12</volume>, <fpage>581767</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2020.581767</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tohda</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>New age therapy for alzheimer&#x27;s disease by neuronal network reconstruction</article-title>. <source>Biol. Pharm. Bull.</source> <volume>39</volume>, <fpage>1569</fpage>&#x2013;<lpage>1575</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.b16-00438</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Kuboyama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tohda</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>A systematic strategy for discovering a therapeutic drug for alzheimer&#x27;s disease and its target molecule</article-title>. <source>Front. Pharmacol.</source> <volume>8</volume>, <fpage>340</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2017.00340</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Kuboyama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tohda</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Naringenin promotes microglial M2 polarization and A&#x3b2; degradation enzyme expression</article-title>. <source>Phytother. Res.</source> <volume>33</volume>, <fpage>1114</fpage>&#x2013;<lpage>1121</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.6305</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>